三元生物首次公开发行股票的发行费用总额为1.39亿元，其中，保荐及承销费用1.21亿元。 中国经济网北京2月27日讯 三元生物(301206.SZ)今日股价下跌，截至收盘报28.55元，跌幅4.07%。 三元生物于2022年2月10日在深交所创业板上市，公开发行3372.10万股，发行价格为109.30元/股， 保荐机构（主承销商）为中信建投证券股份有限公司，保荐代表人为陆丹君、陈磊。 上市首日，三元生物创下上市以来最高价报146.00元。该股目前处于破发状态。 三元生物首次公开发行股票募集资金总额为36.86亿元，扣除发行费用后募集资金净额为35.47亿 元。该公司最终募集资金净额比原计划多26.47亿元。三元生物于2022年1月28日披露的招股说明书显 示，该公司拟募集资金9.00亿元，分别用于年产50000吨赤藓糖醇及技术中心项目、研发信息中心建设 项目、补充流动资金。 2022年6月10日，三元生物披露了2021年年度权益分派实施公告。公司2021年年度权益分派方案 为：以公司现有总股本1.35亿股为基数，向全体股东每10股派10元现金（含税），同时，以资本公积金 向全体股东每10股转增5股。分红前公 ...

证券代码：301206 证券简称：三元生物 公告编号：2026-012 山东三元生物科技股份有限公司 1 / 4 关于部分募集资金专户销户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于深圳证券交易所创 业板首次公开发行股票募集资金按照相关法律、法规及规范性文件的规定在银行 开立了募集资金专用账户。近日，公司募集资金专用账户的注销手续已经办理完 成，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）核准，并经深圳证券 交易所同意，公司向社会公众公开发行人民币普通股（A 股）3,372.10 万股，每 股面值为人民币 1.00 元，发行价格为人民币 109.3 元/股，募集资金总额为人民 币 368,570.53 万元。扣除承销费和其他发行费用，募集资金净额为人民币 354,664.46 万元，上述募集资金到位情况业经上会会计师事务所（特殊普通合伙） 以"上会师报字【2022】第 ...

格隆汇2月26日｜A股代糖概念股短线拉升，其中，保龄宝封涨停板，三元生物、金禾实业、华康股份 等跟涨。 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 国枫律股字[2026]A0063 号 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 证券代码：301206 证券简称：三元生物 公告编号：2026-011 山东三元生物科技股份有限公司 2026 年第一次临时股东会决议公告 5、会议主持人：董事长聂在建 6、会议召开情况的合法、合规性说明：本次会议的召集、召开与表决程序 符合《公司法》《深圳证券交易所创业板股票上市规则》及《公司章程》的有关 规定，所作决议合法有效。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2026 年 2 月 24 日（星期二）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2026 年 2 月 24 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2026 年 2 月 24 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召 ...

Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]

Core Viewpoint - San Yuan Bio announced that as of February 10, 2026, the company has a total of 15,658 registered shareholders [2] Company Summary - The company is actively engaging with investors through interactive platforms, indicating a focus on transparency and communication [2] - The number of registered shareholders reflects the company's growth and potential interest from the investment community [2]

Group 1 - The core viewpoint of the article highlights that the domestic ex-factory price of erythritol in the United States is considered non-public commercial information and is typically higher than that of Chinese export products due to local energy, labor, and raw material costs [1] - The company will continue to monitor global price trends and aims to maintain its core competitiveness through technological innovation and cost optimization in response to changes in the international trade environment [1]

Group 1 - The company is actively providing samples of Reb M to domestic and international potential clients, with some clients already incorporating it into their sugar-reduction product formulations [2] - Tagatose, as a key focus for the company, is currently in a critical phase of market promotion and industrial application, with steady progress being made [2] - The company has utilized Reb M in the formulation of products containing erythritol and allulose, enhancing product quality and market competitiveness [2]

Core Viewpoint - The final ruling on anti-dumping and countervailing duties ("double anti") against Chinese erythritol products has been announced, with the leading company, Sanyuan Biotech, facing a maximum combined tax rate of 93.58%, significantly impacting its market competitiveness in the U.S. [1][2] Group 1: Tax Rates and Impact - Sanyuan Biotech has been assigned a countervailing duty rate of 8.63% and an anti-dumping duty rate of 84.95%, leading to a total tax rate of 93.58% [1][2] - The company did not qualify for separate rate status, resulting in a unified tax rate of 184.26% for other exporters, although this is a reduction from the initial rate of 450.64% [2] - The high tax rates are expected to diminish Sanyuan's cost competitiveness in the U.S. market, leading to potential order reductions and market share loss [2][3] Group 2: Market Dynamics and Alternatives - The U.S. market for sweeteners is significant, with 30%-40% of beverages being imported, indicating ongoing demand despite the tariff challenges [3] - Sanyuan Biotech can explore alternative market strategies, such as changing product forms to bypass tariffs or utilizing third-party channels for U.S. market entry [4] - The company is also developing alternatives to erythritol, such as allulose, which is projected to be a strategic sweetener with lower calories and a taste profile similar to sucrose [5] Group 3: Future Prospects and Innovations - Sanyuan Biotech is focusing on technological innovation to extend its product offerings beyond traditional sugar alcohols, which are already cost-effective due to mature production processes [5] - The company aims to tap into emerging markets in Southeast Asia, India, the Middle East, and South America as part of its growth strategy [4][5]